Found: 2
Select item for more details and to access through your institution.
Idarubicin and cytarabine in combination with gemtuzumab ozogamicin (IAGO) for untreated patients with high-risk MDS or AML evolved from MDS: a phase II study from the EORTC and GIMEMA Leukemia Groups (protocol 06013).
- Published in:
- 2015
- By:
- Publication type:
- journal article
Survival Improvement over Time of 960 s-AML Patients Included in 13 EORTC-GIMEMA-HOVON Trials.
- Published in:
- Cancers, 2020, v. 12, n. 11, p. 3334, doi. 10.3390/cancers12113334
- By:
- Publication type:
- Article